## 117TH CONGRESS 1ST SESSION

## H. R. 2435

To amend the Federal Food, Drug, and Cosmetic Act to require the label of a drug that is intended for human use and contains an ingredient that is derived directly or indirectly from a gluten-containing grain to identify each such ingredient, and for other purposes.

## IN THE HOUSE OF REPRESENTATIVES

APRIL 8, 2021

Mr. Ryan (for himself and Mr. Stivers) introduced the following bill; which was referred to the Committee on Energy and Commerce

## A BILL

To amend the Federal Food, Drug, and Cosmetic Act to require the label of a drug that is intended for human use and contains an ingredient that is derived directly or indirectly from a gluten-containing grain to identify each such ingredient, and for other purposes.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "Gluten in Medicine
- 5 Disclosure Act of 2021".

1	SEC. 2. LABELING OF DRUGS WITH AN INGREDIENT MADE
2	FROM A GLUTEN-CONTAINING GRAIN.
3	(a) Misbranding.—Section 502 of the Federal
4	Food, Drug, and Cosmetic Act (21 U.S.C. 352) is amend-
5	ed by adding at the end the following:
6	"(gg) If it is a drug—
7	"(1) that is intended for human use;
8	"(2) that contains an ingredient that is derived
9	directly or indirectly from a gluten-containing grain
10	(including wheat, barley, rye, and their crossbred hy-
11	brids); and
12	"(3) whose label fails—
13	"(A) to state that the drug contains such
14	an ingredient; and
15	"(B) to identify each such ingredient and
16	the type of gluten-containing grain from which
17	it is derived.".
18	(b) Applicability.—Section 502(gg) of the Federal
19	Food, Drug, and Cosmetic Act, as added by subsection
20	(a) of this section, shall apply beginning on the sooner
21	of—
22	(1) a date to be determined by the Secretary of
23	Health and Human Services; and
24	(2) the date that is 2 years after the date of the
25	enactment of this Act